Makers Laboratories Share Price
Sector: Major Drugs
165.35 +27.30 (19.78%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
141.90
Today’s High
165.65
52 Week Low
114.00
52 Week High
230.00
Key Metrics
- Market Cap (In Cr) 97.59
- Beta 2.54
- Div. Yield (%) 0
- P/B 1.29
- TTM P/E 17.02
- Peg Ratio -
- Sector P/E 24.5
- Open Price 142.35
- Prev Close 138.05
Makers Laboratories Analysis
Price Analysis
-
1 Week5.95%
-
3 Months-4.79%
-
6 Month-10.94%
-
YTD-23.39%
-
1 Year-2.95%
Risk Meter
- 58% Low risk
- 58% Moderate risk
- 58% Balanced Risk
- 58% High risk
- 58% Extreme risk
Makers Laboratories News
Home remedy: Indian pharma bets on domestic brands to fight US generics slowdown
4 min read . 08 Nov 2024Makers Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 104.39
- Selling/ General/ Admin Expenses Total
- 13.94
- Depreciation/ Amortization
- 4.54
- Other Operating Expenses Total
- 34.93
- Total Operating Expense
- 107.84
- Operating Income
- -3.45
- Net Income Before Taxes
- -3.92
- Net Income
- -6.26
- Diluted Normalized EPS
- -10.62
- Period
- 2024
- Total Assets
- 161.26
- Total Liabilities
- 98.21
- Total Equity
- 63.05
- Tangible Book Valueper Share Common Eq
- 104.94
- Period
- 2024
- Cashfrom Operating Activities
- 0.84
- Cashfrom Investing Activities
- -6.89
- Cashfrom Financing Activities
- 5.74
- Net Changein Cash
- -0.31
- Period
- 2023
- Total Revenue
- 101.28
- Selling/ General/ Admin Expenses Total
- 14.73
- Depreciation/ Amortization
- 4.24
- Other Operating Expenses Total
- 28.32
- Total Operating Expense
- 101.82
- Operating Income
- -0.54
- Net Income Before Taxes
- -0.84
- Net Income
- -4.75
- Diluted Normalized EPS
- -8.06
- Period
- 2023
- Total Assets
- 152.3
- Total Liabilities
- 83.09
- Total Equity
- 69.2
- Tangible Book Valueper Share Common Eq
- 116.06
- Period
- 2023
- Cashfrom Operating Activities
- -8.62
- Cashfrom Investing Activities
- 1.25
- Cashfrom Financing Activities
- 5.78
- Net Changein Cash
- -1.59
- Period
- 2022
- Total Revenue
- 126.63
- Selling/ General/ Admin Expenses Total
- 15.01
- Depreciation/ Amortization
- 4.02
- Other Operating Expenses Total
- 30
- Total Operating Expense
- 112.02
- Operating Income
- 14.6
- Net Income Before Taxes
- 15.69
- Net Income
- 4.98
- Diluted Normalized EPS
- 10.44
- Period
- 2022
- Total Assets
- 144.33
- Total Liabilities
- 84.75
- Total Equity
- 59.58
- Tangible Book Valueper Share Common Eq
- 120.71
- Period
- 2022
- Cashfrom Operating Activities
- 8.5
- Cashfrom Investing Activities
- -11.79
- Cashfrom Financing Activities
- 0.33
- Net Changein Cash
- -2.96
- Period
- 2021
- Total Revenue
- 68.64
- Selling/ General/ Admin Expenses Total
- 11.33
- Depreciation/ Amortization
- 4.61
- Other Operating Expenses Total
- 13.08
- Total Operating Expense
- 64.96
- Operating Income
- 3.68
- Net Income Before Taxes
- 2.7
- Net Income
- -0.33
- Diluted Normalized EPS
- -0.64
- Period
- 2021
- Total Assets
- 136.19
- Total Liabilities
- 82.06
- Total Equity
- 54.13
- Tangible Book Valueper Share Common Eq
- 104.98
- Period
- 2021
- Period
- 2020
- Total Revenue
- 51.4
- Selling/ General/ Admin Expenses Total
- 8.89
- Depreciation/ Amortization
- 1.99
- Other Operating Expenses Total
- 7.61
- Total Operating Expense
- 50.26
- Operating Income
- 1.13
- Net Income Before Taxes
- 0.25
- Net Income
- -0.12
- Diluted Normalized EPS
- -0.18
- Period
- 2020
- Total Assets
- 73.88
- Total Liabilities
- 29.26
- Total Equity
- 44.62
- Tangible Book Valueper Share Common Eq
- 86.93
- Period
- 2020
- Cashfrom Operating Activities
- 4.23
- Cashfrom Investing Activities
- -8.43
- Cashfrom Financing Activities
- 2.91
- Net Changein Cash
- -1.29
- Period
- 2019
- Total Revenue
- 46.63
- Selling/ General/ Admin Expenses Total
- 13.28
- Depreciation/ Amortization
- 1.5
- Other Operating Expenses Total
- -1.7
- Total Operating Expense
- 43.75
- Operating Income
- 2.87
- Net Income Before Taxes
- 3.02
- Net Income
- 2.45
- Diluted Normalized EPS
- 4.79
- Period
- 2019
- Total Assets
- 60.01
- Total Liabilities
- 18.31
- Total Equity
- 41.7
- Tangible Book Valueper Share Common Eq
- 81.37
- Period
- 2019
- Cashfrom Operating Activities
- 5.39
- Cashfrom Investing Activities
- -8.31
- Cashfrom Financing Activities
- 3.92
- Net Changein Cash
- 1
- Period
- 2024-12-31
- Total Revenue
- 27.69
- Selling/ General/ Admin Expenses Total
- 3.18
- Depreciation/ Amortization
- 1.31
- Other Operating Expenses Total
- 9.89
- Total Operating Expense
- 27.69
- Operating Income
- 0
- Net Income Before Taxes
- 0.68
- Net Income
- -0.3
- Diluted Normalized EPS
- -0.5
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 29.57
- Selling/ General/ Admin Expenses Total
- 3.65
- Depreciation/ Amortization
- 1.29
- Other Operating Expenses Total
- 11.44
- Total Operating Expense
- 28.56
- Operating Income
- 1.01
- Net Income Before Taxes
- 11.09
- Net Income
- 8.82
- Diluted Normalized EPS
- 14.76
- Period
- 2024-09-30
- Total Assets
- 150.11
- Total Liabilities
- 79.21
- Total Equity
- 70.9
- Tangible Book Valueper Share Common Eq
- 118.36
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1.43
- Cashfrom Investing Activities
- 13.72
- Cashfrom Financing Activities
- -14.43
- Net Changein Cash
- 0.72
- Period
- 2024-06-30
- Total Revenue
- 29.59
- Selling/ General/ Admin Expenses Total
- 3.63
- Depreciation/ Amortization
- 1.28
- Other Operating Expenses Total
- 9.67
- Total Operating Expense
- 29.96
- Operating Income
- -0.36
- Net Income Before Taxes
- -0.47
- Net Income
- -0.98
- Diluted Normalized EPS
- -0.69
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 27.81
- Selling/ General/ Admin Expenses Total
- 3.51
- Depreciation/ Amortization
- 1.15
- Other Operating Expenses Total
- 7.36
- Total Operating Expense
- 28.06
- Operating Income
- -0.25
- Net Income Before Taxes
- -0.38
- Net Income
- -1.29
- Diluted Normalized EPS
- -2.18
- Period
- 2024-03-31
- Total Assets
- 161.26
- Total Liabilities
- 98.21
- Total Equity
- 63.05
- Tangible Book Valueper Share Common Eq
- 104.94
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 0.84
- Cashfrom Investing Activities
- -6.89
- Cashfrom Financing Activities
- 5.74
- Net Changein Cash
- -0.31
- Period
- 2023-12-31
- Total Revenue
- 26.51
- Selling/ General/ Admin Expenses Total
- 3.37
- Depreciation/ Amortization
- 1.16
- Other Operating Expenses Total
- 7.87
- Total Operating Expense
- 27.46
- Operating Income
- -0.95
- Net Income Before Taxes
- -1.12
- Net Income
- -1.54
- Diluted Normalized EPS
- -2.61
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Makers Laboratories Technical
Moving Average
SMA
- 5 Day138.65
- 10 Day137.72
- 20 Day142.11
- 50 Day140
- 100 Day155.85
- 300 Day156.09
Makers Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Welcure Drugs And Pharmaceutic
- 11.44
- -0.27
- -2.31
- 15.81
- 4.3
- 128.27
- Bharat Immunologica And Bio Corp
- 24.36
- 0.98
- 4.19
- 35.88
- 19
- 105.91
- Makers Laboratories
- 165.35
- 27.3
- 19.78
- 230
- 114
- 97.59
- Ind Swift
- 15.12
- 0.4
- 2.72
- 34.49
- 12
- 82.57
- Zenlabs Ethica
- 32.84
- 0.04
- 0.12
- 52.1
- 27.33
- 21.38
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Welcure Drugs And Pharmaceutic
- -
- 11.8
- -6.66
- -49.3
- Bharat Immunologica And Bio Corp
- -
- 1.15
- -23.67
- -16.7
- Makers Laboratories
- -
- 1.29
- -2.32
- 1.31
- Ind Swift
- 4.29
- -
- -
- -1.44
- Zenlabs Ethica
- 80
- 2.05
- 6.1
- 0.94
Makers Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 26-May-25
- Audited Results
- 29-Jan-25
- Quarterly Results
- 29-Oct-24
- Quarterly Results
- 06-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results
- 13-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 22-May-23
- Audited Results
- 13-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 06-Aug-24
- 11-Jul-24
- AGM
- 14-Aug-23
- 22-May-23
- AGM
- 18-Aug-21
- 22-Jul-21
- AGM



- Announced on
- Record Date
- Ex-Rights Date
- Ratio
- FV
- Premium
- Description
- 10-Nov-21
- 01-Apr-22
- 30-Mar-22
- 1:5
- 10
- 140
- Rights issue of equity shares of Rs. 10/- each in the ratio of 1:5 @ premium of Rs. 140/-.